SUBSCRIBE
SUBSCRIBE
News   Policy

Novartis AG Withdraws Joicela Marketing Application in Europe

April 19, 2011 | 
1 min read

Bloomberg -- Novartis AG (NOVN) withdrew its application to market the Joicela pain pill in the European Union because the Swiss company wasn’t able to provide information to regulators in the time allowed.

Regulatory Europe
Novartis
MORE ON THIS TOPIC
Amgen sign at its headquarters in Thousand Oaks, California, USA.
Approvals
Looking Beyond Obesity, Amgen Wins Colorectal Cancer Expansion for Lumakras
January 17, 2025
 · 
2 min read
 · 
Tristan Manalac
Novartis' office building in Marburg, Germany
Patents
Novartis Scrambles to Squelch Copycats as Generics Gain Ground
January 17, 2025
 · 
2 min read
 · 
Tristan Manalac
Pictured: Exterior view of the headquarters of the
Complete response letters
Manufacturing Issues Result in FDA Rejection of Atara’s Cell Therapy
January 16, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
FDA signage at its headquarters in Maryland
Regulatory
After Letter to Commissioner, FDA Finally Gives Vanda Reason for Rejection, Chance for Hearing
January 16, 2025
 · 
2 min read
 · 
Tristan Manalac